Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety

Am J Clin Nutr. 2013 May;97(5):980-9. doi: 10.3945/ajcn.112.047563. Epub 2013 Mar 6.

Abstract

Background: Effects of protein intake on appetite-regulating hormones and their dynamics are unclear.

Objectives: We investigated the satiating effects of meals with varying protein contents and whether there was an effect of dose on appetite-regulating hormones and appetite ratings.

Design: Twenty-five men [mean ± SD age: 30.0 ± 8.7 y; body mass index (BMI; in kg/m(2)): 25.9 ± 4.7] participated in the 3-way, randomized, double-blind crossover study. Test meals were isocaloric with 30% of energy from fat and protein content adjusted at the expense of carbohydrate. Test meals were normal protein (NP; 14% of energy from protein), medium-high protein (MHP; 25% of energy from protein), and high protein (HP, 50% of energy from protein). Appetite ratings and blood samples were assessed every 0.5 h for 4 h. An ad libitum lunch was served 4 h after the meal.

Results: Protein increased dose-dependently glucagon-like peptide-1 (GLP-1), peptide YY (PYY) 3-36, and glucagon; MHP produced 10%, 7%, and 47% greater responses, respectively; and HP produced 20%, 14%, and 116% greater responses, respectively, than did NP (P < 0.03). Compared with NP, HP increased insulin and cholecystokinin and decreased ghrelin and glucose-dependent insulinotropic polypeptide (P < 0.05). Satiety and fullness dose-dependently increased by 7% and 6% for MHP and 16% and 19% for HP compared with NP (P < 0.001). Hunger and prospective consumption dose-dependently decreased by 15% and 13% for MHP and by 25% and 26% for HP compared with NP (P < 0.0003). There was a combined effect of GLP-1 and PYY 3-36 (P = 0.03) next to the additive effect of GLP-1 (P = 0.006) on the composite appetite score. No difference was shown in ad libitum energy intake.

Conclusion: Protein dose-dependently increased satiety and GLP-1, PYY 3-36, and glucagon, which may, at least in part, be responsible for the satiety-stimulating effect of protein. This trial was registered at clinicaltrials.gov as NCT01561235.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Appetite / physiology*
  • Blood Glucose / analysis
  • Cholecystokinin / blood
  • Cholecystokinin / physiology
  • Cross-Over Studies
  • Dietary Proteins / administration & dosage*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Energy Intake
  • Gastrointestinal Hormones / blood
  • Gastrointestinal Hormones / physiology*
  • Ghrelin / blood
  • Ghrelin / physiology
  • Glucagon / blood
  • Glucagon / physiology
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / physiology
  • Humans
  • Hunger / physiology
  • Insulin / blood
  • Insulin / physiology
  • Male
  • Pancreatic Hormones / blood
  • Pancreatic Hormones / physiology*
  • Peptide YY / blood
  • Peptide YY / physiology
  • Satiation / physiology*
  • Young Adult

Substances

  • Blood Glucose
  • Dietary Proteins
  • Gastrointestinal Hormones
  • Ghrelin
  • Insulin
  • Pancreatic Hormones
  • Peptide YY
  • Glucagon-Like Peptide 1
  • Glucagon
  • Cholecystokinin

Associated data

  • ClinicalTrials.gov/NCT01561235